EGFR and non-small cell lung carcinoma: Currently, EGFR tyrosine kinase inhibitors (EGFR-TKIs) have been recommended by many guidelines as the standard first-line therapy for patients with EGFR mutation-positive advanced NSCLC (Wang et al., 2021; Ettinger et al., 2022).